It's ironic, no doubt, that the big Allina nurses strike — round two of which opened last week — is chiefly about health care costs.
And it's instructive that the fiercest dispute concerns the health care system's wish to shift nurses to health insurance plans that require more out-of-pocket payment from patients — higher deductibles and copays — while generally lowering insurance premiums.
Nothing, it seems, makes vivid the high cost of certain things like asking people to pay with their own money each time they use those things. And not just in health care.
Higher education stirs similar frustrations these days. Nearly all Americans agree that higher ed, like health care, is profoundly valuable. And, more than ever, they also agree that both of these priceless possessions cost way too much.
We'd like to pay less for many commodities. But politicians seldom vow to tame the runaway cost of cars or cabbages or cargo shorts. We seem to detect something particularly unhealthy, even a little dumb, about our health care and higher-ed marketplaces. It's worth asking what they may have in common.
In health care, the sickening price increases of many brand-name prescription drug products are again raising temperatures. Minnesota's U.S. Sen. Amy Klobuchar has lately led a political chorus (which includes Hillary Clinton) in denouncing the soaring price of the EpiPen, a device that delivers a lifesaving antidote to victims of allergic shock. But the critics make it clear that they consider U.S. pharmaceutical prices to be painfully swollen across the board and in need of a public policy antidote.
Such complaints aren't new. But outrage over prescription drug prices had quieted a bit in the early 2000s, after enactment of Medicare's "Part D" extended prescription drug insurance for America's senior citizens. Before that, seniors often paid for drugs with their own money. One hasn't heard so many claims since about elderly subsisting on dog food in order to afford their medicines.
It's the growing trend in more recent years toward higher "cost-sharing" in employer-based insurance — the very trend Allina's nurses resist being swept up in — that reignited the prescription drug wars.